Efficacy and safety of tislelizumab as neoadjuvant treatment in patients with stage II–III microsatellite instability-high/mismatch repair-deficient colorectal cancer: a single-arm, multicenter, open-label, prospective, phase II study
This study provides promising preliminary evidence for the efficacy and safety of neoadjuvant tislelizumab in patients with locally advanced MSI-H/dMMR CRC.
Authors
- Dalu Kong (ORCID: https://orcid.org/0000-0003-2036-1332)
- Chang Li (ORCID: https://orcid.org/0000-0002-3267-1859)
- Ye Yao (ORCID: https://orcid.org/0000-0002-0878-8942)
- Yue Liu
- Mulin Liu (ORCID: https://orcid.org/0000-0003-2655-5402)
- Kefeng Ding
- S. Wei
- Yanlai Sun
- Dandan Li
- Lilin Zhang
- Yanbing Zhou
- Jingdong Zhang
- Juan Zhang
- Liyun Li
- Gong Chen
- Yang Gao
Institutions
- Qingdao University (CN)
- Sun Yat-sen University (CN)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Zhejiang Cancer Hospital (CN)
- Beijing Enterprises (China) (CN)
- Affiliated Hospital of Qingdao University (CN)
- Sun Yat-sen University Cancer Center (CN)
- First Affiliated Hospital of Bengbu Medical College (CN)
- Shanghai Clinical Research Center (CN)
- Hubei Cancer Hospital (CN)
- Liaoning Cancer Hospital & Institute (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- International Journal of Surgery
- Published
- 2026-02-18
- DOI
- https://doi.org/10.1097/js9.0000000000004836
- Primary Topic
- Genetic factors in colorectal cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00